Acumen Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$1.59next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
| ALTITUDE-AD Phase 2 Topline Data Announcement | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly128.4MTarget: Sufficient to fund operations into early 2027
ALTITUDE-AD Phase 2 Trial Enrollment Annually542.0Target: 542 (Enrollment completed)
Quarterly Net Loss Quarterly-20.7M
Watch Items
- ALTITUDE-AD Phase 2 Topline Data ReadoutTrigger: Late 2026Action: Evaluate primary clinical efficacy endpoint (iADRS) and secondary endpoints (CDR-SB, ARIA safety rates) to determine Phase 3 advancement strategy.
- EBD Program IND FilingTrigger: Mid-2027Action: Monitor preclinical progress of the two licensed candidates (bispecific derived from sabirnetug and ACU234) to ensure timely IND submission.
- Cash Runway and Capital AllocationTrigger: Early 2027 cash depletionAction: Assess financing options, including potential public offerings, partnerships, or non-dilutive funding, to extend runway beyond the Phase 2 readout.
Research as of 19 Jun 2026